CN116920069B - Traditional Chinese medicine extract and application thereof in promoting umbilical cord stem cells to secrete VEGF - Google Patents
Traditional Chinese medicine extract and application thereof in promoting umbilical cord stem cells to secrete VEGF Download PDFInfo
- Publication number
- CN116920069B CN116920069B CN202310822600.5A CN202310822600A CN116920069B CN 116920069 B CN116920069 B CN 116920069B CN 202310822600 A CN202310822600 A CN 202310822600A CN 116920069 B CN116920069 B CN 116920069B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- mesenchymal stem
- traditional chinese
- cells
- medicine extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 134
- 239000000284 extract Substances 0.000 title claims abstract description 89
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title claims abstract description 45
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title claims abstract description 45
- 210000003954 umbilical cord Anatomy 0.000 title claims abstract description 44
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 22
- 230000001737 promoting effect Effects 0.000 title claims abstract description 21
- 239000006228 supernatant Substances 0.000 claims abstract description 19
- 241001289529 Fallopia multiflora Species 0.000 claims abstract description 15
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 15
- 240000002924 Platycladus orientalis Species 0.000 claims abstract description 14
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 14
- 235000008397 ginger Nutrition 0.000 claims abstract description 14
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 13
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 108
- 210000004027 cell Anatomy 0.000 claims description 76
- 239000006143 cell culture medium Substances 0.000 claims description 53
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 35
- 238000012258 culturing Methods 0.000 claims description 31
- 238000001914 filtration Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 14
- 241000234314 Zingiber Species 0.000 claims description 13
- 230000008014 freezing Effects 0.000 claims description 13
- 238000007710 freezing Methods 0.000 claims description 13
- 230000028327 secretion Effects 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- 238000002474 experimental method Methods 0.000 claims description 7
- 235000015110 jellies Nutrition 0.000 claims description 7
- 239000008274 jelly Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 4
- 238000011010 flushing procedure Methods 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 238000005374 membrane filtration Methods 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 241000212322 Levisticum officinale Species 0.000 claims 1
- 240000001341 Reynoutria japonica Species 0.000 claims 1
- 235000018167 Reynoutria japonica Nutrition 0.000 claims 1
- 239000001645 levisticum officinale Substances 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 abstract description 8
- 231100000360 alopecia Toxicity 0.000 abstract description 8
- 238000004113 cell culture Methods 0.000 abstract description 8
- 210000003780 hair follicle Anatomy 0.000 abstract description 7
- 208000027418 Wounds and injury Diseases 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 5
- 208000014674 injury Diseases 0.000 abstract description 5
- 230000008439 repair process Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- 210000004209 hair Anatomy 0.000 abstract description 3
- 230000003248 secreting effect Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- 238000002835 absorbance Methods 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 241000125175 Angelica Species 0.000 description 3
- 235000001287 Guettarda speciosa Nutrition 0.000 description 3
- 102000009521 Vascular Endothelial Growth Factor B Human genes 0.000 description 3
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 2
- 102100023118 Transcription factor JunD Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 210000000264 venule Anatomy 0.000 description 2
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 1
- 210000001956 EPC Anatomy 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150030763 Vegfa gene Proteins 0.000 description 1
- 101150091393 Vegfb gene Proteins 0.000 description 1
- 101150036482 Vegfc gene Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000012865 aseptic processing Methods 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a traditional Chinese medicine extract and application thereof in promoting umbilical cord stem cells to secrete VEGF, and belongs to the technical field of medicines. According to the invention, the Chinese medicinal extract is prepared from the Chinese angelica, the polygonum multiflorum, the ligusticum wallichii, the biota orientalis and the dried ginger, so that the Chinese medicinal prescription is convenient to obtain materials and has low cost; the traditional Chinese medicine extract is used for promoting the umbilical cord stem cells to secrete VEGF, the traditional Chinese medicine technology is combined with the modern stem cell culture technology, umbilical cord stem cells capable of secreting more vascular endothelial growth factors are cultured, and the umbilical cord stem cells and the supernatant containing the vascular endothelial growth factors and the traditional Chinese medicine extract play a role in auxiliary repair of hair follicle injury and alopecia, so that the trouble of hair rarefaction and alopecia is solved.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a traditional Chinese medicine extract and application thereof in promoting umbilical cord stem cells to secrete VEGF.
Background
The umbilical cord stem cells generally refer to umbilical cord mesenchymal stem cells, are derived from umbilical cord tissues of newborns, are separated and extracted from Wharton's jelly, are stem cells with self-renewal and multiple differentiation potential, have low immunogenicity and strong proliferation capability, and can be used for repairing damaged or diseased tissue organs, strengthening the immunoregulatory capability of organisms, promoting hematopoietic function repair and the like. In recent years, the medicine is widely applied and researched in a plurality of medical treatment fields. Numerous studies have demonstrated that umbilical cord mesenchymal stem cells are capable of secreting different types of cytokines, such as vascular endothelial growth factor (Vascular Endothelial Growth Factor, VEGF), fibroblast growth factor (Fibroblast Growth Factor, FGF), etc., which can optimize the microenvironment surrounding damaged skin tissue, promote proliferation of damaged tissue cells, accelerate healing of the injured site, etc.
VEGF is widely distributed in organs of heart, brain, kidney, bones, skin and other tissues of human and animals, can enhance the permeability of venules and venules, promote the formation of new blood vessels and the growth of vascular endothelial cells, and is the factor with highest specificity and strongest activity for promoting angiogenesis at present. Research shows that VEGF plays a vital role in preventing and treating cardiovascular and cerebrovascular diseases and chronic kidney diseases, growing and developing bone tissues, generating and developing tumors, regenerating scalp hair and repairing wound surfaces.
For example, patent CN110327458a discloses that vascular endothelial growth factor B (VEGF-B) is a metabolic regulator of selective secretion of different subtypes of activated T cells, activating T cells by antibodies or peptides, and/or inducing activated T cells to secrete VEGF-B by ROS/AP-1 signaling pathway using agonists capable of promoting mitochondrial biosynthesis or agents that regulate mitochondrial related ROS/AP-1 signaling, thereby promoting fatty acid uptake, anti-apoptosis, anti-tumor activity, etc. of T cells.
In the history of the development of Chinese medicine with a great popularity, the application of Chinese herbal medicines is more and more extensive, and a plurality of Chinese herbal medicines are verified to have the pharmacological actions of anti-inflammatory, anti-infection, antimicrobial, antiviral, anti-tumor, nerve protection, immunoregulation, blood vessel protection and the like under the support of modern scientific experiment technology, so that the research background of modern pharmacy and pharmacology is also laid for treating various diseases by applying Chinese medicinal formulas. Research shows that the Chinese medicine can promote the secretion of vascular endothelial growth factor, and as patent CN111249293A discloses the new application of astragaloside in promoting EPCs to secrete vascular growth factor (VEGFa, VEGFb, VEGFc, FGF, ang-1) and exosome. However, due to the instability of the active ingredients of the herbal extracts at the laboratory level and the requirement for aseptic processing, traditional Chinese medicine techniques are less applicable in relevant cell culture experiments. And at present, no related technical report exists that in the umbilical cord stem cell culture process, the vascular endothelial growth factor is promoted to be secreted by the umbilical cord stem cell through the induction of traditional Chinese medicines, and the cell culture supernatant containing traditional Chinese medicine components and the vascular endothelial growth factor and the induced cells are applied to hair follicle repair and hair growth. Therefore, the application of the traditional Chinese medicine to promote the secretion of VEGF by umbilical cord mesenchymal stem cells has important significance.
Disclosure of Invention
In order to solve the defects of the prior art, the invention provides a traditional Chinese medicine extract and application thereof in promoting umbilical cord stem cells to secrete VEGF, combines a traditional Chinese medicine technology with a cell culture process, is used for promoting mesenchymal stem cells to secrete VEGF level, solves the problem of stability of traditional Chinese medicine components in experiments, improves the level of secreted vascular endothelial growth factor, and is combined with added traditional Chinese medicine components to promote hair follicle repair and hair regeneration, thereby helping people to solve the problem of alopecia.
In order to achieve the above purpose, the present invention provides the following technical solutions:
In one aspect, the invention provides a traditional Chinese medicine prescription, which comprises 5-18 parts of Chinese angelica, 12-16 parts of polygonum multiflorum, 3-6 parts of ligusticum wallichii, 8-12 parts of biota orientalis and 8-13 parts of dried ginger.
Preferably, the Chinese medicinal prescription comprises 10 parts of Chinese angelica, 15 parts of polygonum multiflorum, 5 parts of ligusticum wallichii, 10 parts of biota orientalis and 10 parts of dried ginger.
The extraction method of the traditional Chinese medicine prescription comprises the following steps:
mixing the above materials, dissolving with water, extracting, and filtering to obtain Chinese medicinal extractive solution.
Preferably, the filtering step comprises: multi-layer gauze filtration, quantitative filter paper filtration and 0.2-0.25um sterile filter membrane filtration.
The application of the traditional Chinese medicine prescription or the traditional Chinese medicine extract in repairing hair follicle injury and treating alopecia comprises the application in promoting the secretion of VEGF by umbilical cord stem cells.
In yet another aspect, the present invention provides a method for promoting the secretion of VEGF by umbilical cord stem cells, comprising the steps of:
A. Separating and preparing mesenchymal stem cells from umbilical cord tissues, and then carrying out passage amplification culture and freezing;
B. Adding the traditional Chinese medicine extract prepared by the extraction method into a mesenchymal stem cell culture medium for culture, and determining the addition concentration of the traditional Chinese medicine extract through experiments;
C. And B, using the mesenchymal stem cell culture medium containing the traditional Chinese medicine extract obtained in the step B for culturing the mesenchymal stem cells.
In some embodiments, in step a, the umbilical cord is a neonatal umbilical cord, stored in normal saline or Phosphate Buffered Saline (PBS) after collection, transported at low temperature (zero), and prepared for no longer than 24 hours from collection.
In other embodiments, the step a includes:
A1, separating Wharton's jelly tissue from a neonatal umbilical cord for later use;
A2, inoculating the Whatman gel tissue blocks into a culture dish, and placing the culture dish in an incubator for preparation;
A3, adding a preheated mesenchymal stem cell culture medium into the culture dish in the step A2, and performing primary culture;
a4, sucking tissue blocks in the culture dish, and collecting cells for subculturing;
A5, transferring the cells to 1 generation, digesting and collecting the cells after the cells grow fully, inoculating the cells into a culture dish, continuously subculturing the cells, and freezing the rest cells;
A6, transferring the cells to 3 generations, digesting and collecting the cells after the cells grow up, and freezing the cells.
Preferably, the step A1 includes: the umbilical cord tissue of the neonate is disinfected and cleaned by alcohol and normal saline, after no microbial contamination of bacteria, fungi, mycoplasma, viruses and the like is detected, the umbilical cord is longitudinally split, three blood vessels (two arteries and one vein) in the umbilical cord are removed by forceps, and then the Wharton's jelly is torn and sheared into tissue blocks with the size of about 1mm 3; wherein 0.5-2% of diabody (penicillin-streptomycin mixed solution) is added into physiological saline.
Preferably, in the step A2, the plating density of the Whatman tissue block is 60-75% of the bottom area of the culture dish.
Preferably, in step A2, the incubator environment is: 3-8% CO 2, 36.5-37.2 ℃, saturated humidity, more preferably 5% CO 2, 37 ℃, saturated humidity; the holding time is 20-50min, more preferably 30min.
Preferably, in the step A3, the mesenchymal stem cell culture medium is added in an amount of 20-35 mL/dish, and more preferably 30 mL/dish.
Preferably, in step A3, the mesenchymal stem cell medium is alpha-MEM, and 4-5.5% of serum replacement is added, and more preferably 5% of serum replacement is added.
Preferably, in the step A3, the culture time is 12-15 days, and the culture medium is half-changed every 3-5 days during the culture.
Preferably, in step A4, the cells grow to cover 45-50% of the area of the bottom of the dish when the tissue mass is aspirated.
Preferably, the step A5 is: cells were transferred to 1 passage, collected by digestion after confluence, plated 1.4X10 6 on 1 150mm dishes for further passage, and the remaining cells were frozen in liquid nitrogen at a density of 5X 10 6/mL as seed cells.
Preferably, in step A6, the cells are frozen at a density of 3-5X 10 6/mL.
In other embodiments, the step B includes:
b1, adding the traditional Chinese medicine extract into a mesenchymal stem cell culture medium;
And B2, resuscitating the frozen 3-generation mesenchymal stem cells, transferring to 5-generation mesenchymal stem cells, re-suspending and inoculating to a mesenchymal stem cell culture medium for culture, discarding the mesenchymal stem cell culture medium, and adding the mesenchymal stem cell culture medium containing the traditional Chinese medicine extract obtained in the step B1 for continuous culture.
Preferably, in the step B1, the concentration of the Chinese medicine extract added to the culture medium is 1-8mL/L.
Further preferably, in step B1, when the concentration of the extract of the traditional Chinese medicine added to the culture medium is 4mL/L, the secretion function of the mesenchymal stem cells is optimal, and the secretion amount of the vascular endothelial growth factor is maximized.
Preferably, the step B2 includes: resuscitate the frozen mesenchymal stem cells for 5 generations, re-suspend the mesenchymal stem cells in 96 well plate, discard the mesenchymal stem cells after 24 hr, replace the prepared mesenchymal stem cells culture medium containing Chinese medicine extract to continue culturing, detect the proliferation rate of the cells in each well, and thus determine the concentration of Chinese medicine extract.
In other embodiments, step C comprises:
Resuscitate the frozen mesenchymal stem cells for 3 generations, transfer to 5 generations, continue culturing, discard supernatant, add the mesenchymal stem cell culture medium containing Chinese medicinal extract, continue culturing.
Preferably, the step C includes:
c1, recovering the frozen 3-generation mesenchymal stem cells, and transferring to 5-generation mesenchymal stem cells;
c2, culturing for 24 hours, discarding supernatant, and adding a mesenchymal stem cell culture medium containing a traditional Chinese medicine extract for culturing;
C3, continuously culturing for 72 hours, collecting supernatant containing vascular endothelial growth factor and the traditional Chinese medicine extract, flushing residual cells with PBS, and adding PBS for continuously culturing;
C4, culturing for 96h, and collecting PBS.
In still another aspect, the invention also provides a composition, which is the supernatant containing the vascular endothelial growth factor and the Chinese medicine extract obtained in the step C3.
The composition can be used for repairing hair follicle injury and treating alopecia.
Compared with the prior art, the invention has the beneficial effects that:
(1) The invention discloses an application of a traditional Chinese medicine extract in promoting umbilical cord stem cells to secrete VEGF, which has strong operability and stable process, and can be suitable for general laboratory academic research and large-scale cell production;
(2) The traditional Chinese medicine material selects traditional Chinese medicine formula particles according to equivalent standard, so that the medicine extraction time is greatly shortened, meanwhile, the stability of different batches of medicinal materials is ensured, the effective components in the traditional Chinese medicine are extracted through a low-temperature sterile process, and the loss of the medicinal components is reduced; the addition amount of the effective component is evaluated on the molecular level, so that the stability of the action effect of the added traditional Chinese medicine component is ensured;
(3) The traditional Chinese medicine technology is combined with the modern stem cell culture technology, mesenchymal stem cells capable of secreting more vascular endothelial growth factors are cultured, and the mesenchymal stem cells and supernatant containing the vascular endothelial growth factors and the Chinese medicine extract play a role in auxiliary repair of hair follicle injury and alopecia, so that the trouble of hair rarefaction and alopecia is solved.
Drawings
In order to more clearly illustrate the embodiments of the invention or the technical solutions in the prior art, the drawings that are required in the embodiments or the description of the prior art will be briefly described, it being obvious that the drawings in the following description are only some embodiments of the invention, and that other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is a diagram showing the growth state of umbilical cord mesenchymal stem cells according to the present invention; in the figure, (a) represents primary cells before passage and (b) represents cells transferred to 3 passages;
FIG. 2 is a graph showing the effect of different concentrations of the Chinese medicinal extract on proliferation rate of umbilical mesenchymal stem cells;
FIG. 3 is a flow chart showing the use of the mesenchymal stem cell medium containing the extract of the Chinese medicine for culturing umbilical cord mesenchymal stem cells.
Detailed Description
The following non-limiting examples will enable those of ordinary skill in the art to more fully understand the invention and are not intended to limit the invention in any way. The following is merely exemplary of the scope of the invention as claimed and many variations and modifications of the invention will be apparent to those skilled in the art in light of the disclosure, which are intended to be within the scope of the invention as claimed.
In the invention, the Phosphate Buffer Solution (PBS) is prepared by dissolving 8g of NaCl, 0.2gKCl g of Na 2HPO4 and 0.24g of gKH 2PO4 in 800mL of distilled water, regulating the pH value of the solution to 7.4 by using HCl, adding distilled water to a volume of 1L, and sterilizing.
The invention is further illustrated by means of the following specific examples. The various chemical reagents used in the examples of the present invention were obtained by conventional commercial means unless otherwise specified.
Example 1
The traditional Chinese medicine prescription comprises the following components: 10g of Chinese angelica, 15g of polygonum multiflorum, 5g of ligusticum wallichii, 10g of biota orientalis and 10g of dried ginger.
Mixing the components in the traditional Chinese medicine prescription, fully mixing with warm water of about 100mL and 50 ℃ for dissolving, filtering residues with multi-layer gauze, quantitatively filtering with filter paper to remove small particulate matters, and filtering with a 0.22um sterile filter membrane for sterilization to obtain the traditional Chinese medicine extract.
The method for promoting the umbilical cord stem cells to secrete VEGF by using the traditional Chinese medicine extract comprises the following steps:
1. Isolated culture of umbilical cord mesenchymal stem cells
(1.1) The neonatal umbilical cord is stored in normal saline after being collected and transported at low temperature, and the time from collection to preparation is not longer than 24 hours;
(1.2) sterilizing and cleaning umbilical cord tissue by using alcohol and normal saline (1% double antibody is added: penicillin-streptomycin mixed solution), longitudinally cutting the umbilical cord after no microbial contamination of bacteria, fungi, mycoplasma, viruses and the like is detected, removing three blood vessels in the umbilical cord, and then tearing Wharton's jelly and shearing into tissue blocks with the size of about 1mm 3;
(1.3) placing the Whatman gum tissue blocks into a 150mm culture dish, spreading uniformly, covering about 70% of the bottom area of the culture dish, and placing the culture dish in a saturated humidity incubator with 5% CO 2 at 37 ℃ for 30min; the dish was removed, and 30mL of a mesenchymal stem cell medium (α -MEM manufactured by Gibco Co., ltd., 5% Helios HPCFDCGL% serum replacement) preheated at 37℃was added; placing into an incubator with 5% CO 2 and 37 ℃ and saturated humidity for culturing;
(1.4) half-dose medium exchange every 5 days, and tissue mass was aspirated when cultured cells grew to cover 50% of the bottom area of the dish, while cells were collected for subculture. Observing the morphology of primary cells before passage by using a light microscope, and as shown in the result of FIG. 1 (a), the cells grow in a spindle-shaped adherent manner and spread along the group edge to the periphery;
(1.5) transferring the cells to 1 generation, digesting and collecting the cells after the cells grow fully, inoculating 1.4X10 6 to 1 culture dish with 150mm, continuing to passage, and freezing the rest cells in liquid nitrogen according to the density of 5X 10 6/mL to obtain seed cells;
(1.6) cells were transferred to 3 passages, and after confluence, the collected cells were digested, frozen in liquid nitrogen at a density of 5X 10 6/mL to give working cells, and the morphology of the 3 passages of cells was observed by a light microscope, and the results are shown in FIG. 1 (b).
2. Determination of additive concentration of Chinese medicine extract
Adding the Chinese medicine extract into a mesenchymal stem cell culture medium according to a plurality of concentrations; resuscitate the frozen mesenchymal stem cells for 5 generations, re-suspend and inoculate the mesenchymal stem cells in 96-well plates (3000 cells/well) for culture, discard the mesenchymal stem cells culture medium after 24 hours, replace the prepared mesenchymal stem cells culture medium containing traditional Chinese medicine extract, and continue to culture for 48 hours in 5 multiple wells per concentration.
Detecting the cell viability of each hole by using an MTT method, and determining the concentration of the traditional Chinese medicine extracting solution when the cell proliferation rate is maximum, wherein the concentration of the traditional Chinese medicine extracting solution added into a culture medium is divided into I groups: 1mL/L, II group: 2mL/L, III group: 4mL/L, IV group: 8mL/L, V group: 16mL/L, VI group: 32mL/L, the group without the Chinese medicine extract was used as a blank control group, the absorbance OD value of each group was tested by MTT kit, and the cell proliferation rate was calculated from the absorbance, and the results are shown in Table 1 and FIG. 2.
MTT assay detection of Medium cell absorbance (n=5, X.+ -. S)
| Group of | Concentration of Chinese medicine extract (mL/L) | Absorbance (OD/490 nm) |
| Blank control group | 0 | 0.3842±0.0122 |
| Ⅰ | 1 | 0.4024±0.0099 |
| Ⅱ | 2 | 0.4809±0.0134* |
| Ⅲ | 4 | 0.5031±0.0406* |
| Ⅳ | 8 | 0.4698±0.0322* |
| Ⅴ | 16 | 0.3804±0.0122 |
| Ⅵ | 32 | 0.2873±0.0144* |
Note that: * For comparison with the control group without added traditional Chinese medicine, P <0.05.
The results of Table 1 were observed: the cell viability is represented by the absorbance OD value of each group, the higher the absorbance, the stronger the cell viability and the maximum cell proliferation rate, as shown in Table 1, when the concentration of the traditional Chinese medicine extract is 1-4mL/L compared with that of the mesenchymal stem cell culture medium without the traditional Chinese medicine extract, the absorbance is increased along with the increase of the adding concentration, the cell viability is enhanced, and the absorbance is reduced and is lower than that of the mesenchymal stem cell culture medium without the traditional Chinese medicine extract along with the further increase of the adding concentration; observe fig. 2: the horizontal axis shows the concentration of the added Chinese medicine extract, the vertical axis shows the cell proliferation rate, and the result shows that compared with the traditional Chinese medicine extract without the addition of the Chinese medicine extract, the cell activity is obviously changed, the cell activity is obviously improved along with the increase of the addition concentration of the Chinese medicine extract within a certain range, and the cytoplasmic proliferation rate reaches the maximum when the addition concentration reaches 4mL/L, but the inhibiting effect can be shown along with the increase of the addition concentration of the Chinese medicine extract. The absorbance corresponds to the result of the cell proliferation rate test, so that the concentration of the traditional Chinese medicine extract added in the mesenchymal stem cell culture medium used in the method is 4 mL/L.
3. Mesenchymal stem cell culture medium containing Chinese medicinal components for culturing mesenchymal stem cells (flow chart shown in figure 3)
(1) Cells were resuscitated and passaged to 5 passages: resuscitate the cryopreserved 3 rd generation mesenchymal stem cells, transfer to 5 th generation;
(2) Cell culture: culturing the cells for 24 hours, discarding the supernatant, and dividing the cells into two groups;
(3) Adding a mesenchymal stem cell culture medium containing a traditional Chinese medicine extract for culture: adding a group of mesenchymal stem cell culture medium containing 4mL/L of traditional Chinese medicine extract, and continuously culturing for 72h;
(4) Adding a mesenchymal stem cell culture medium without a traditional Chinese medicine extract for culture: adding the other group of mesenchymal stem cell culture medium without adding the traditional Chinese medicine extract as a control group, and continuously culturing for 72 hours under the same condition as the step (3);
(5) Collecting supernatant containing vascular endothelial growth factor and Chinese medicinal extractive solution: collecting the supernatant containing the vascular endothelial growth factor and the traditional Chinese medicine extract in the steps (3) and (4), flushing the rest cells twice by using PBS, adding the PBS for continuous culture for 96 hours, collecting the PBS, and detecting the concentration of the vascular endothelial growth factor secreted by the two groups of mesenchymal stem cells by using an ELISA method.
Example 2
Example 2 differs from example 1 in that the traditional Chinese medicine formulation in this example comprises the following components: 14g of Chinese angelica, 15g of polygonum multiflorum, 5g of ligusticum wallichii, 8g of biota orientalis and 8g of dried ginger; the remainder was the same as in example 1.
Example 3
Example 3 differs from example 1 in that the traditional Chinese medicine formulation in this example comprises the following components: 5g of Chinese angelica, 15g of polygonum multiflorum, 5g of ligusticum wallichii, 12g of biota orientalis and 13g of dried ginger; the remainder was the same as in example 1.
Comparative example 1
Comparative example 1 differs from example 1 in that the traditional Chinese medicine formulation in this example comprises the following components: 15g of Chinese angelica, 15g of polygonum multiflorum, 5g of ligusticum wallichii, 10g of biota orientalis and 5g of dried ginger; the remainder was the same as in example 1.
Comparative example 2
Comparative example 2 differs from example 1 in that the traditional Chinese medicine formulation in this example comprises the following components: 6g of angelica, 15g of polygonum multiflorum, 5g of ligusticum wallichii, 10g of biota orientalis and 14g of dried ginger; the remainder was the same as in example 1.
Comparative example 3
Comparative example 3 differs from example 1 in that the traditional Chinese medicine formulation in this example comprises the following components: 14g of Chinese angelica, 15g of polygonum multiflorum, 5g of ligusticum wallichii, 6g of biota orientalis and 10g of dried ginger; the remainder was the same as in example 1.
Comparative example 4
Comparative example 4 differs from example 1 in that the traditional Chinese medicine formulation in this example comprises the following components: 7g of angelica, 15g of polygonum multiflorum, 5g of ligusticum wallichii, 13g of biota orientalis and 10g of dried ginger; the remainder was the same as in example 1.
Comparative example 5
Comparative example 5 differs from example 1 in that the traditional Chinese medicine formulation in this comparative example comprises the following components: 20g of Chinese angelica, 15g of polygonum multiflorum, 5g of ligusticum wallichii and 10g of dried ginger; the remainder was the same as in example 1.
Comparative example 6
Comparative example 6 differs from example 1 in that the traditional Chinese medicine formulation in this comparative example comprises the following components: 20g of Chinese angelica, 15g of polygonum multiflorum, 5g of ligusticum wallichii and 10g of biota orientalis; the remainder was the same as in example 1.
Comparative example 7
Comparative example 7 differs from example 1 in that the traditional Chinese medicine formulation in this comparative example comprises the following components: 30g of angelica, 15g of polygonum multiflorum and 5g of ligusticum wallichii; the remainder was the same as in example 1.
The results of the final measurement of the concentration of the secreted vascular endothelial growth factor by the method for promoting the secretion of VEGF by umbilical cord stem cells using the extract of traditional Chinese medicine described in the above examples and comparative examples are shown in Table 2 below.
ELISA method for measuring cell VEGF concentration in culture Medium (n=5, X.+ -. S)
Note that: * For comparison with the control group without added traditional Chinese medicine, P <0.05.
As shown in table 2, when the traditional Chinese medicine extract (control group) is not added into the mesenchymal stem cell culture medium, the concentration of the obtained Vascular Endothelial Growth Factor (VEGF) is 8.9882pg/mL, and after the traditional Chinese medicine extract is added, the concentration of the obtained vascular endothelial growth factor is obviously improved, so that the traditional Chinese medicine extract can promote umbilical mesenchymal stem cells to promote the secretion of vascular endothelial growth factor.
In summary, the invention provides a traditional Chinese medicine extract and an application thereof in promoting the secretion of VEGF by umbilical cord stem cells, a certain amount of traditional Chinese medicine components have a promoting effect on the proliferation of umbilical cord mesenchymal stem cells, but with the increase of the addition amount, the traditional Chinese medicine extract has a inhibiting effect, and has a certain instability in laboratory application due to the influence of various factors such as the production place, the collection time method, the storage method, the processing method and the like. The invention utilizes a non-high temperature and sterile process to extract the traditional Chinese medicine extract, and reserves the effective components of the traditional Chinese medicine to the maximum extent. The method combines the traditional Chinese medicine technology of China with the modern cell culture, and the related products can be further applied to the fields of repairing hair follicle injury, alopecia and the like.
The previous description of the embodiments is provided to facilitate a person of ordinary skill in the art in order to make and use the present invention. It will be apparent to those skilled in the art that various modifications can be readily made to these embodiments and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above-described embodiments, and those skilled in the art, based on the present disclosure, should make improvements and modifications without departing from the scope of the present invention.
Claims (3)
1. The application of the traditional Chinese medicine extract in promoting the secretion of VEGF by umbilical cord stem cells is characterized in that the traditional Chinese medicine extract is prepared according to the following method:
Mixing the components of the traditional Chinese medicine prescription, fully mixing with water, dissolving, extracting, and filtering to obtain traditional Chinese medicine extract;
The filtering step comprises the following steps: multi-layer gauze filtration, quantitative filter paper filtration and 0.2-0.25um aseptic filter membrane filtration,
The traditional Chinese medicine prescription consists of the following components: 10 parts of Chinese angelica, 15 parts of tuber fleeceflower root, 5 parts of szechuan lovage rhizome, 10 parts of biota orientalis leaf and 10 parts of dried ginger,
The application comprises the steps of:
A. Separating and preparing mesenchymal stem cells from umbilical cord tissues, and then carrying out passage amplification culture and freezing;
B. Adding the traditional Chinese medicine extract into a mesenchymal stem cell culture medium for culture, and determining the adding concentration of the traditional Chinese medicine extract through experiments;
C. the mesenchymal stem cell culture medium containing the traditional Chinese medicine extract liquid obtained in the step B is used for culturing the mesenchymal stem cells,
Wherein:
The step A comprises the following steps:
A1, separating Wharton's jelly tissue from a neonatal umbilical cord for later use;
A2, inoculating the Whatman gel tissue blocks into a culture dish, and placing the culture dish in an incubator for preparation;
A3, adding a preheated mesenchymal stem cell culture medium into the culture dish in the step A2, and performing primary culture;
a4, sucking tissue blocks in the culture dish, and collecting cells for subculturing;
A5, transferring the cells to 1 generation, digesting and collecting the cells after the cells grow fully, inoculating the cells into a culture dish, continuously subculturing the cells, and freezing the rest cells;
a6, transferring the cells to 3 generations, digesting and collecting the cells after the cells grow up, freezing,
In the step A3, the mesenchymal stem cell culture medium is alpha-MEM, and 4-5.5% of serum substitute is added;
The step B comprises the following steps:
b1, adding the traditional Chinese medicine extract into a mesenchymal stem cell culture medium;
B2, resuscitating the frozen 3-generation mesenchymal stem cells, transferring to 5-generation mesenchymal stem cells, re-suspending and inoculating to a mesenchymal stem cell culture medium for culture, discarding the mesenchymal stem cell culture medium, adding the mesenchymal stem cell culture medium containing the traditional Chinese medicine extract obtained in the step B1 for continuous culture,
In the step B1, the concentration of the traditional Chinese medicine extracting solution added into the culture medium is 4mL/L;
The step C comprises the following steps:
resuscitate the frozen mesenchymal stem cells for 3 generations, transfer to 5 generations, continue to culture, discard supernatant, add the mesenchymal stem cell culture medium containing the Chinese medicine extract to continue to culture,
The step of adding the mesenchymal stem cell culture medium containing the traditional Chinese medicine extract for continuous culture comprises the following steps:
c1, recovering the frozen 3-generation mesenchymal stem cells, and transferring to 5-generation mesenchymal stem cells;
c2, culturing for 24 hours, discarding supernatant, and adding a mesenchymal stem cell culture medium containing a traditional Chinese medicine extract for culturing;
C3, continuously culturing for 72 hours, collecting supernatant containing vascular endothelial growth factor and the traditional Chinese medicine extract, flushing residual cells with PBS, and adding PBS for continuously culturing;
C4, culturing for 96h, and collecting PBS.
2. A method for promoting secretion of VEGF by umbilical cord stem cells, comprising the steps of:
A. Separating and preparing mesenchymal stem cells from umbilical cord tissues, and then carrying out passage amplification culture and freezing;
B. Adding the traditional Chinese medicine extract into a mesenchymal stem cell culture medium for culture, and determining the adding concentration of the traditional Chinese medicine extract through experiments; the traditional Chinese medicine extract is prepared according to the following method:
Mixing the components of the traditional Chinese medicine prescription, fully mixing with water, dissolving, extracting, and filtering to obtain traditional Chinese medicine extract;
The filtering step comprises the following steps: multi-layer gauze filtration, quantitative filter paper filtration and 0.2-0.25um aseptic filter membrane filtration,
The traditional Chinese medicine prescription consists of the following components: 10 parts of Chinese angelica, 15 parts of polygonum multiflorum, 5 parts of ligusticum wallichii, 10 parts of biota orientalis leaves and 10 parts of dried ginger;
C. the mesenchymal stem cell culture medium containing the traditional Chinese medicine extract liquid obtained in the step B is used for culturing the mesenchymal stem cells,
Wherein:
The step A comprises the following steps:
A1, separating Wharton's jelly tissue from a neonatal umbilical cord for later use;
A2, inoculating the Whatman gel tissue blocks into a culture dish, and placing the culture dish in an incubator for preparation;
A3, adding a preheated mesenchymal stem cell culture medium into the culture dish in the step A2, and performing primary culture;
a4, sucking tissue blocks in the culture dish, and collecting cells for subculturing;
A5, transferring the cells to 1 generation, digesting and collecting the cells after the cells grow fully, inoculating the cells into a culture dish, continuously subculturing the cells, and freezing the rest cells;
a6, transferring the cells to 3 generations, digesting and collecting the cells after the cells grow up, freezing,
In the step A3, the mesenchymal stem cell culture medium is alpha-MEM, and 4-5.5% of serum substitute is added;
The step B comprises the following steps:
b1, adding the traditional Chinese medicine extract into a mesenchymal stem cell culture medium;
B2, resuscitating the frozen 3-generation mesenchymal stem cells, transferring to 5-generation mesenchymal stem cells, re-suspending and inoculating to a mesenchymal stem cell culture medium for culture, discarding the mesenchymal stem cell culture medium, adding the mesenchymal stem cell culture medium containing the traditional Chinese medicine extract obtained in the step B1 for continuous culture,
In the step B1, the concentration of the traditional Chinese medicine extracting solution added into the culture medium is 4mL/L;
The step C comprises the following steps:
resuscitate the frozen mesenchymal stem cells for 3 generations, transfer to 5 generations, continue to culture, discard supernatant, add the mesenchymal stem cell culture medium containing the Chinese medicine extract to continue to culture,
The step of adding the mesenchymal stem cell culture medium containing the traditional Chinese medicine extract for continuous culture comprises the following steps:
c1, recovering the frozen 3-generation mesenchymal stem cells, and transferring to 5-generation mesenchymal stem cells;
c2, culturing for 24 hours, discarding supernatant, and adding a mesenchymal stem cell culture medium containing a traditional Chinese medicine extract for culturing;
C3, continuously culturing for 72 hours, collecting supernatant containing vascular endothelial growth factor and the traditional Chinese medicine extract, flushing residual cells with PBS, and adding PBS for continuously culturing;
C4, culturing for 96h, and collecting PBS.
3. A composition, characterized in that it is prepared according to the following method:
A. Separating and preparing mesenchymal stem cells from umbilical cord tissues, and then carrying out passage amplification culture and freezing;
B. Adding the traditional Chinese medicine extract into a mesenchymal stem cell culture medium for culture, and determining the adding concentration of the traditional Chinese medicine extract through experiments; the traditional Chinese medicine extract is prepared according to the following method:
Mixing the components of the traditional Chinese medicine prescription, fully mixing with water, dissolving, extracting, and filtering to obtain traditional Chinese medicine extract;
The filtering step comprises the following steps: multi-layer gauze filtration, quantitative filter paper filtration and 0.2-0.25um aseptic filter membrane filtration,
The traditional Chinese medicine prescription consists of the following components: 10 parts of Chinese angelica, 15 parts of polygonum multiflorum, 5 parts of ligusticum wallichii, 10 parts of biota orientalis leaves and 10 parts of dried ginger;
C. B, using the mesenchymal stem cell culture medium containing the traditional Chinese medicine extract obtained in the step B for culturing mesenchymal stem cells, and collecting supernatant containing vascular endothelial growth factors and the traditional Chinese medicine extract to obtain the composition;
Wherein:
The step A comprises the following steps:
A1, separating Wharton's jelly tissue from a neonatal umbilical cord for later use;
A2, inoculating the Whatman gel tissue blocks into a culture dish, and placing the culture dish in an incubator for preparation;
A3, adding a preheated mesenchymal stem cell culture medium into the culture dish in the step A2, and performing primary culture;
a4, sucking tissue blocks in the culture dish, and collecting cells for subculturing;
A5, transferring the cells to 1 generation, digesting and collecting the cells after the cells grow fully, inoculating the cells into a culture dish, continuously subculturing the cells, and freezing the rest cells;
a6, transferring the cells to 3 generations, digesting and collecting the cells after the cells grow up, freezing,
In the step A3, the mesenchymal stem cell culture medium is alpha-MEM, and 4-5.5% of serum substitute is added;
The step B comprises the following steps:
b1, adding the traditional Chinese medicine extract into a mesenchymal stem cell culture medium;
B2, resuscitating the frozen 3-generation mesenchymal stem cells, transferring to 5-generation mesenchymal stem cells, re-suspending and inoculating to a mesenchymal stem cell culture medium for culture, discarding the mesenchymal stem cell culture medium, adding the mesenchymal stem cell culture medium containing the traditional Chinese medicine extract obtained in the step B1 for continuous culture,
In the step B1, the concentration of the traditional Chinese medicine extracting solution added into the culture medium is 4mL/L;
The step C comprises the following steps:
resuscitate the frozen mesenchymal stem cells for 3 generations, transfer to 5 generations, continue to culture, discard supernatant, add the mesenchymal stem cell culture medium containing the Chinese medicine extract to continue to culture,
The step of adding the mesenchymal stem cell culture medium containing the traditional Chinese medicine extract for continuous culture comprises the following steps:
c1, recovering the frozen 3-generation mesenchymal stem cells, and transferring to 5-generation mesenchymal stem cells;
c2, culturing for 24 hours, discarding supernatant, and adding a mesenchymal stem cell culture medium containing a traditional Chinese medicine extract for culturing;
and C3, continuously culturing for 72 hours, and collecting supernatant containing vascular endothelial growth factor and the traditional Chinese medicine extract to obtain the composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310822600.5A CN116920069B (en) | 2023-07-06 | 2023-07-06 | Traditional Chinese medicine extract and application thereof in promoting umbilical cord stem cells to secrete VEGF |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310822600.5A CN116920069B (en) | 2023-07-06 | 2023-07-06 | Traditional Chinese medicine extract and application thereof in promoting umbilical cord stem cells to secrete VEGF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116920069A CN116920069A (en) | 2023-10-24 |
| CN116920069B true CN116920069B (en) | 2024-05-17 |
Family
ID=88383624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310822600.5A Active CN116920069B (en) | 2023-07-06 | 2023-07-06 | Traditional Chinese medicine extract and application thereof in promoting umbilical cord stem cells to secrete VEGF |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116920069B (en) |
Citations (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1043624A (en) * | 1988-12-23 | 1990-07-11 | 杭文敬 | Primary regenerant |
| CN101422528A (en) * | 2007-11-02 | 2009-05-06 | 绿谷（集团）有限公司 | Alopecia prevention composition and production method thereof |
| CN102018771A (en) * | 2010-11-05 | 2011-04-20 | 王秀峰 | Hair anti-dropping medical pilatory |
| CN102676452A (en) * | 2012-04-26 | 2012-09-19 | 天津美德太平洋科技有限公司 | Culture medium containing human umbilical cord mesenchymal stem cell exudates and preparation method and applications thereof |
| KR20120126284A (en) * | 2011-05-11 | 2012-11-21 | (주)안트로젠 | Method for preparation of mesenchymal stem cell culture comprising high concentration of cell growth factors and composition prepared therefrom |
| CN104546574A (en) * | 2013-10-17 | 2015-04-29 | 刘俊 | Anti-dandruff and hair-loss-preventing traditional Chinese medicine shampoo and producing method thereof |
| CN105431521A (en) * | 2013-02-28 | 2016-03-23 | 哈佛学院校长同事会 | Methods and compositions for mobilizing stem cells |
| CN106389764A (en) * | 2016-09-23 | 2017-02-15 | 浙江省中医院 | Traditional Chinese medicine preparation, and preparation and application thereof |
| CN108707199A (en) * | 2018-05-29 | 2018-10-26 | 廊坊康宝汇泰生物技术有限公司 | Target Chimeric antigen receptor T cell and its application of TEM8 |
| CN110540958A (en) * | 2019-04-08 | 2019-12-06 | 启迪汉洱康（嘉兴）生物科技有限公司 | Preparation of umbilical cord mesenchymal stem cell secretory factor and application thereof in hair growth |
| CN110904049A (en) * | 2019-12-05 | 2020-03-24 | 伯仕利生物科技发展（盐城）有限公司 | Preparation method and application of stem cell supernatant rich in VEGF and FGF |
| CN110964689A (en) * | 2019-11-27 | 2020-04-07 | 浙江卫未生物医药科技有限公司 | Method for restoring dryness or proliferation capacity of hair follicle source cells |
| CN111172103A (en) * | 2019-12-05 | 2020-05-19 | 伯仕利生物科技发展（盐城）有限公司 | Preparation method and application of stem cell exosome stimulated by angelica sinensis extract |
| CN112294697A (en) * | 2019-07-31 | 2021-02-02 | 欣绿智国际企业有限公司 | Method for producing water molecule natural hair-care liquid and water molecule natural hair-care liquid |
| CN113116970A (en) * | 2019-12-31 | 2021-07-16 | 湖南省南华生物医药研究所 | Stem cell skin repair liquid containing gardenia jasminoides extract and preparation method thereof |
| KR20210122719A (en) * | 2020-04-01 | 2021-10-12 | 주식회사 프리모리스 | Manufacturing method and usage of conditioned media which contains highly effective exosomes secreted by umbilical cord blood stem cells at high content |
| CN113633588A (en) * | 2021-08-14 | 2021-11-12 | 广州市丝露杰精细化工有限公司 | Anti-hair loss shampoo and preparation method thereof |
| CN114042145A (en) * | 2021-11-29 | 2022-02-15 | 苏州诺威百奥生物科技有限公司 | Novel exosome hydrolysis sponge hair growth promoting liquid |
| CN114874982A (en) * | 2022-07-07 | 2022-08-09 | 山东省齐鲁干细胞工程有限公司 | Culture method for enhancing umbilical cord mesenchymal stem cells to secrete vascular endothelial growth factors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2349976B1 (en) * | 2009-05-14 | 2011-11-10 | Sanidad Y Residencias 21 Sa | USE OF OLIVE LEAF EXTRACTS IN A PHARMACEUTICAL COMPOSITION TO INDUCE ANGIOGENESIS AND VASCULOGENESIS. |
| WO2014027965A1 (en) * | 2012-08-15 | 2014-02-20 | National University Of Singapore | Wound dressing nanomesh impregnated with human umbilical cord wharton's jelly stem cells |
| WO2018236131A1 (en) * | 2017-06-20 | 2018-12-27 | 주식회사 툴젠 | Angiopoietin-1- or vegf-secreting stem cell and pharmaceutical composition for prevention or treatment of cardiovascular disease, comprising same |
| CN116083355B (en) * | 2023-03-09 | 2023-12-01 | 广东赛尔生物科技有限公司 | Method for improving therapeutic capacity of umbilical mesenchymal stem cells |
-
2023
- 2023-07-06 CN CN202310822600.5A patent/CN116920069B/en active Active
Patent Citations (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1043624A (en) * | 1988-12-23 | 1990-07-11 | 杭文敬 | Primary regenerant |
| CN101422528A (en) * | 2007-11-02 | 2009-05-06 | 绿谷（集团）有限公司 | Alopecia prevention composition and production method thereof |
| CN102018771A (en) * | 2010-11-05 | 2011-04-20 | 王秀峰 | Hair anti-dropping medical pilatory |
| KR20120126284A (en) * | 2011-05-11 | 2012-11-21 | (주)안트로젠 | Method for preparation of mesenchymal stem cell culture comprising high concentration of cell growth factors and composition prepared therefrom |
| CN102676452A (en) * | 2012-04-26 | 2012-09-19 | 天津美德太平洋科技有限公司 | Culture medium containing human umbilical cord mesenchymal stem cell exudates and preparation method and applications thereof |
| CN105431521A (en) * | 2013-02-28 | 2016-03-23 | 哈佛学院校长同事会 | Methods and compositions for mobilizing stem cells |
| CN104546574A (en) * | 2013-10-17 | 2015-04-29 | 刘俊 | Anti-dandruff and hair-loss-preventing traditional Chinese medicine shampoo and producing method thereof |
| CN106389764A (en) * | 2016-09-23 | 2017-02-15 | 浙江省中医院 | Traditional Chinese medicine preparation, and preparation and application thereof |
| CN108707199A (en) * | 2018-05-29 | 2018-10-26 | 廊坊康宝汇泰生物技术有限公司 | Target Chimeric antigen receptor T cell and its application of TEM8 |
| CN110540958A (en) * | 2019-04-08 | 2019-12-06 | 启迪汉洱康（嘉兴）生物科技有限公司 | Preparation of umbilical cord mesenchymal stem cell secretory factor and application thereof in hair growth |
| CN112294697A (en) * | 2019-07-31 | 2021-02-02 | 欣绿智国际企业有限公司 | Method for producing water molecule natural hair-care liquid and water molecule natural hair-care liquid |
| CN110964689A (en) * | 2019-11-27 | 2020-04-07 | 浙江卫未生物医药科技有限公司 | Method for restoring dryness or proliferation capacity of hair follicle source cells |
| CN110904049A (en) * | 2019-12-05 | 2020-03-24 | 伯仕利生物科技发展（盐城）有限公司 | Preparation method and application of stem cell supernatant rich in VEGF and FGF |
| CN111172103A (en) * | 2019-12-05 | 2020-05-19 | 伯仕利生物科技发展（盐城）有限公司 | Preparation method and application of stem cell exosome stimulated by angelica sinensis extract |
| CN113116970A (en) * | 2019-12-31 | 2021-07-16 | 湖南省南华生物医药研究所 | Stem cell skin repair liquid containing gardenia jasminoides extract and preparation method thereof |
| KR20210122719A (en) * | 2020-04-01 | 2021-10-12 | 주식회사 프리모리스 | Manufacturing method and usage of conditioned media which contains highly effective exosomes secreted by umbilical cord blood stem cells at high content |
| CN113633588A (en) * | 2021-08-14 | 2021-11-12 | 广州市丝露杰精细化工有限公司 | Anti-hair loss shampoo and preparation method thereof |
| CN114042145A (en) * | 2021-11-29 | 2022-02-15 | 苏州诺威百奥生物科技有限公司 | Novel exosome hydrolysis sponge hair growth promoting liquid |
| CN114874982A (en) * | 2022-07-07 | 2022-08-09 | 山东省齐鲁干细胞工程有限公司 | Culture method for enhancing umbilical cord mesenchymal stem cells to secrete vascular endothelial growth factors |
Non-Patent Citations (10)
| Title |
|---|
| Effects of triptolide on bone marrow-derived mesenchymal stem cells from patients with multiple myeloma;Haiying Wu，等;Exp Ther Med.;20190531;第17卷(第5期);第3291-3298页 * |
| 复方斑秃灵搽剂治疗斑秃疗效观察;邹德明;中国皮肤性病学杂志;-;19990620;第-卷(第03期);第176-177页 * |
| 当归对人脐血间充质干细胞增殖的影响;郑婵娟，等;中国康复理论与实践;20100915;第12卷(第11期);第973-975页 * |
| 生发酊联合曲安奈德注射液治疗斑秃的疗效观察;刘小连;谌莉媚;严张仁;;实用中西医结合临床;-;20130925;第-卷(第06期);第34-35页 * |
| 生发酊配合梅花针治疗斑秃;傅黎晖, 陈晓英;福建中医药;-;19970618;第-卷(第03期);第15页 * |
| 肾脑复元汤联合人脐带间充质干细胞移植对MCAO大鼠神经功能恢复及VEGF表达的影响;胡国恒;侯小花;李映辰;王小菊;邹婷;;中国中医急症;20160115(第01期);第4-7页 * |
| 芎归方协同BMSCs-exosomes调控缺血性脑卒中血管新生的实验研究;刘婉莹;《中国优秀硕士学位论文全文数据库(电子期刊)医药卫生科技辑》;20210415(第4期);E057-234 * |
| 补肾中药对大鼠BMSCs分泌NGFβ、BDNF、VEGF功能的影响;刘永琦;蔡玲;颜春鲁;范萍;吴晓晶;孙少伯;;免疫学杂志;20101001(第10期);第850-853页 * |
| 辨证施护联合中药外搽治疗斑秃效果观察;邹学敏;付相钰;张利君;;护理学杂志;-;20080105;第-卷(第01期);第42-43页 * |
| 通心络联合干细胞移植对糖尿病足大鼠促血管新生的影响;李晓琳;高怀林;李彬;王海荣;刘焕;王胜;;疑难病杂志;20180326(第03期);第61-65页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116920069A (en) | 2023-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2076588B1 (en) | Expansion method for adult stem cells from blood, particularly peripheral blood, and relative application in medical field | |
| CN106982821A (en) | Umbilical cord mesenchymal stem cells clinic freezes protection liquid composition and application thereof | |
| CN105687244B (en) | A kind of preparation, preparation method and its application | |
| JP2015503918A (en) | Methods and compositions for induction of medical use of allogeneic cells and therapeutic uses | |
| CN108348555A (en) | Methods for cell expansion and therapeutic combination | |
| CN107254443A (en) | A kind of inducing culture and abductive approach of promotion Differentiation of Marrow Stromal Stem Cells Into Neurons | |
| CN108192862A (en) | A kind of preparation method of pilose antler stem cell, pilose antler stem cell and its application | |
| CN108057116A (en) | Application of the stem cell composition in skin injury medicine | |
| CN107384858A (en) | A kind of preparation method and applications of hypoxic tolerance type mescenchymal stem cell | |
| CN104212762B (en) | Method for culture of urine-derived pluripotent stem cells by virtue of in vitro small molecule induction | |
| CN108865986A (en) | For repairing articular cartilage damage/defect mescenchymal stem cell preparation and its preparation method and application | |
| CN105395571A (en) | New application of small exosome secreted by mesenchymal stem cells in treatment of myocardial infarction | |
| CN107550935A (en) | A kind of biological gel for treating joint disease and its application | |
| CN106497875A (en) | The application of stephanine and a kind of culture medium of amplification placental hematopoietic stem cell and method | |
| CN107488627A (en) | A kind of biological gel for treating intractable skin injury and its application | |
| CN108066750A (en) | Stem cell and its secretion are used to treat the new application of skin burn | |
| CN113559273A (en) | Pretreatment method of adult stem cells for intravenous injection, adult stem cell injection and application | |
| CN105597088A (en) | Preparation and preparation method and application thereof | |
| CN108373995A (en) | A kind of stem cell conditioned medium, preparation method and use | |
| CN116920069B (en) | Traditional Chinese medicine extract and application thereof in promoting umbilical cord stem cells to secrete VEGF | |
| CN109864964B (en) | Anti-aging composition containing stem cells and application thereof | |
| CN109963573A (en) | The manufacturing method of cell preparation and cell preparation | |
| CN108066824A (en) | A kind of new method for preparing skin blemish medicine | |
| CN109939128A (en) | A kind of neural stem cell preparation and preparation method thereof | |
| CN108143748A (en) | A kind of dog MSC excretion body preparations and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |